A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Phase 1

Active, not recruiting

• Conditions: Moderate to Severe Dysphagia; Esophagogastric Cancer
• Interventions: Drug: WST 11-mediated VTP therapy

• Registration Number: NCT03133650
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-26
• Study First Submitted: 2017-04-26
• Study First Submitted QC: 2017-04-26
• Study First Posted: 2017-04-28
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-29
• Last Update Posted: 2024-07-30
• Primary Completion: 2025-02-23
• Study Completion: 2025-02-23

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Age 18 or older

• Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at MSKCC

• Has incurable disease defined as at least one of the following:

  • Presence of metastases to other organs (Stage IV), now or previously
  • Has locally advanced disease and are not candidates for surgery or more radiation treatment
  • Has received the maximal radiation therapy to the primary site, or has been assessed by radiation oncology as not being a candidate for chemoradiation therapy.

• Karnofsky performance status >/= 50%

• No endoluminal stent in place at the time of treatment

• Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure

• Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) </= 7 days prior to treatment

• Prior radiation or surgery to the esophagus is permitted for patients with locally recurrent/persistent disease

• Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2)

• Adequate organ function defined at baseline as:

  • ANC ≥1,000/ L
  • Platelets ≥75,000/ L
  • Hb ≥8.5 g/dl
  • INR ≤1.5 (except for patients who are on full-dose warfarin)
  • Calculated creatinine clearance ≥50 ml/min (using Cockcroft-Gault method)
  • Total serum bilirubin ≤1.5 mg/dL, or </= 2.5 mg/dL for patients with a known history of Gilbert's syndrome
  • AST/ALT ≤5× upper limit of normal

• Able to provide written informed consent

Read More

Exclusion Criteria

• Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include:

  • Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic ≥12 consecutive months)
  • Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml
  • Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence of where the partner is sterile

• T4 tumors with involvement of any adjacent structure, including the trachea, aorta or pleura

• Prior history of esophageal perforation

• Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vascular-targeted photodynamic therapy (VTP) using WST11	WST 11-mediated VTP therapy	Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.

Primary Outcome Measures

Name	Time	Method
Maximum tolerated laser fluence rate	60 days	The maximally tolerated laser light fluence rate (mW/cm) of light exposure for VTP of malignant obstruction due to esophagogastric cancer will be measured by examining 6 fluence rates beginning with a fluence rate of 150 nW/cm, then increasing by 50mW/cm, up to a maximum of 400 mW/cm (150, 200, 250 300, 350, 400).

Trial Locations

Locations (3)

Memorial Sloan - Kettering Cancer Center; 🇺🇸 New York, New York, United States

Weill Cornell Medical Center (Data Analysis Only); 🇺🇸 New York, New York, United States

Weizmann Institute of Science; 🇮🇱 Reẖovot, Israel